TFA
BMRN icon

Transamerica Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Transamerica Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6K Hold
28
– – ﹤0.01% 1360
2026
Q1 		$1.58K Buy
28
+14
+100% +$816 ﹤0.01% 1256
2025
Q4 		$832 Sell
14
-14
-50% -$762 ﹤0.01% 1267
2025
Q3 		$1.52K Buy
+28
New +$1.6K ﹤0.01% 1097

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Transamerica Financial Advisors's BMRN Position: Q2 2026 in Review

Transamerica Financial Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 28 shares worth $1.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1360.

Transamerica Financial Advisors first reported a position in BMRN in Q3 2025 and has held it in 4 quarters since. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Transamerica Financial Advisors held 28 shares of BioMarin Pharmaceuticals worth $1.6K as of Q2 2026.
  • Transamerica Financial Advisors left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1360 holding.
  • Transamerica Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.